Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Promises 12-Month Moratorium On DTC For Newly Launched Products

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will focus on educating medical professionals during the first year a drug is on the market under a new DTC communication code. When products are advertised to consumers, Bristol will target "appropriate" populations, the firm says.

You may also be interested in...



Pfizer Guidelines Call For Physician Education For Six Months Prior To DTC

Stay on DTC is more specific than PhRMA’s DTC guiding principles, which require an “appropriate amount of time” be spent on physician education prior to campaign launch.

Pfizer Guidelines Call For Physician Education For Six Months Prior To DTC

Stay on DTC is more specific than PhRMA’s DTC guiding principles, which require an “appropriate amount of time” be spent on physician education prior to campaign launch.

Sen. Frist's Diagnosis On DTC: GAO Report, Two-Year Moratorium For New Drugs

Majority Leader Frist requests Government Accountability Office examine FDA's oversight of direct-to-consumer ads and their impact on drug usage and costs. The senator also requests drug companies voluntarily restrict DTC ads during the first two years a product is on the market.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel